Novici Biotech produces recombinant proteins such as antibodies, therapeutics, and vaccines in plants and provides DNA error correction technology for the synthetic biology industry. One of the company’s key technologies focuses on making recombinant proteins in plants. Expressing recombinant proteins in plants facilitates rapid development turnaround times, is animal-free, affordable, scalable, leverages a higher eukaryotic host, and enables host manipulation. It produces proteins such as monoclonal antibodies, single domain & VHH antibodies, viral glycoproteins, enzymes, and immunomodulators. The company’s other technologies include GRAMMR and plant host engineering. Novici Biotech is a privately held company.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.